Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 19Thoracic 4Genitourinary 4Gastrointestinal 3Breast 3Head & Neck 2Sarcoma 1Other neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 11Triple Negative Breast Neoplasms 3Melanoma 3Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Urinary Bladder Neoplasms 1Testicular Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Lung Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Disease Progression 1Carcinoma, Renal Cell 1Carcinoma, Pancreatic Ductal 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Biliary Tract Neoplasms 1Anatomic Stage II Breast Cancer AJCC v8 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 44Cyclophosphamide 21Nivolumab 18fludarabine 10durvalumab 8Paclitaxel 8Magnetic Resonance Spectroscopy 8Interleukin-2 8Docetaxel 8aldesleukin 7Radiosurgery 7Ipilimumab 7spartalizumab 6poly ICLC 6fludarabine phosphate 6atezolizumab 6Specimen Handling 6Radiotherapy 6Carboplatin 6cemiplimab 5Drug Therapy 5Cisplatin 5Biopsy 5Temozolomide 4Immune Checkpoint Inhibitors 4tremelimumab 3technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 3pazopanib 3avelumab 3Trastuzumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Melanoma × tremelimumab × Breast × Clear all
NCT02639026 2025-11-25

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Abramson Cancer Center at Penn Medicine

Phase 1 Completed
53 enrolled
BreastDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Ludwig Institute for Cancer Research

Phase 1/2 Completed
58 enrolled 24 charts
BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

NCT02586987 2019-11-18

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
58 enrolled
BreastDermatologicGastrointestinalThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡